Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics develops RNA medicines intended to restore protein expression, using its TANGO approach and antisense oligonucleotides for diseases caused by insufficient gene output. Its lead investigational medicine, zorevunersen, is in development for Dravet syndrome, with earlier work directed at rare genetic neurodevelopmental and other haploinsufficiency diseases.
Company news commonly covers zorevunersen clinical data, EMPEROR study updates, financial results, capital resources, collaboration activity, board and governance changes, equity inducement grants under Nasdaq rules, and healthcare conference presentations.
Stoke Therapeutics (Nasdaq: STOK) will present at two investor conferences in June 2026. CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will speak at the Jefferies Global Healthcare Conference on June 4 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami.
Live webcasts and archived replays will be available in the Investors & News section of Stoke Therapeutics’ website.
Stoke Therapeutics (Nasdaq: STOK) granted stock options to eight new employees as material inducement awards under Nasdaq Listing Rule 5635(c)(4), effective May 15, 2026. The grants cover 106,200 shares at an exercise price of $30.08 per share.
Options vest over four years and have a 10-year term.
Stoke Therapeutics (Nasdaq: STOK) reported Q1 2026 results and new 4-year Phase 1/2a OLE data for zorevunersen in Dravet syndrome. The OLE shows statistically significant improvements in cognition and behavior at 1–4 years and durable reductions in major motor seizures through four years.
As of March 31, 2026, cash, cash equivalents and marketable securities totaled $411.0 million, including $80.7 million from selective ATM sales, expected to fund operations into 2028. Phase 3 EMPEROR enrollment is nearing completion (~130 randomized of ~150; final randomization expected June 2026) to support a mid-2027 data readout and a planned rolling U.S. NDA starting in Q1 2027.
Stoke Therapeutics (Nasdaq: STOK) will host a webcast and conference call on Thursday, May 7, 2026 at 4:30 p.m. ET to discuss first-quarter 2026 business and financial updates.
The live webcast is available on the Investors & News section of Stoke's website, registration is required for analysts who wish to participate in Q&A, and a replay will be archived for at least 90 days.
Stoke Therapeutics (Nasdaq: STOK) granted stock options effective April 15, 2026, as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The company granted options to purchase an aggregate of 129,565 shares to 14 new employees at an exercise price of $35.54 per share (closing price on April 15, 2026). Options vest over four years (25% after one year, then monthly over 36 months) and have a 10-year term, subject to the 2023 Inducement Plan and each option agreement.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 3:00 p.m. ET. A live webcast and archived replay will be available in the Investors & News section of Stoke's website.
Stoke Therapeutics (Nasdaq: STOK) appointed Clare Kahn, Ph.D. to its Board of Directors on April 7, 2026. Dr. Kahn brings 30+ years of regulatory strategy and drug development experience in rare genetic diseases, including roles at X-VAX, Pfizer, and GlaxoSmithKline.
Her addition is positioned to support advancement of zorevunersen as the company progresses its Phase 3 study in Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective March 16, 2026, as material inducements under Nasdaq Listing Rule 5635(c)(4). The company granted options to purchase an aggregate of 58,650 shares to six new employees at an exercise price of $33.96 per share.
Each option vests over four years (25% after one year, then monthly over 36 months), has a 10-year term, and is subject to the 2023 Inducement Plan and related stock option agreements.
Stoke Therapeutics (BIIB) announced that CEO Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live audio webcast and archived replay will be available in the Investors & News section of Stoke’s website.
The company is focused on RNA medicine and is developing zorevunersen as a potential first-in-class disease-modifying treatment for Dravet syndrome.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options effective February 17, 2026, to five new employees totaling 22,950 shares under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $31.09 (closing price on February 17, 2026), vest over four years with standard 1/4 one-year cliff and monthly vesting thereafter, and have a 10-year term under the 2023 Inducement Plan and related agreements.